Clinical Trial Update: RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rollover treatment with Triumeq for amyotrophic lateral sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Triumeq (dolutegravir/abacavir/lamivudine)

Snippet

Sponsor: Macquarie University, Australia | Conditions: Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Status: TERMINATED